Gem Pharmaceuticals Llc - Net Worth and Insider Trading

Gem Pharmaceuticals Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gem Pharmaceuticals Llc owns 1 companies in total, including Monopar Therapeutics Inc (MNPR) .

Click here to see the complete history of Gem Pharmaceuticals Llc’s form 4 insider trades.

Insider Ownership Summary of Gem Pharmaceuticals Llc

Ticker	Comapny	Transaction Date	Type of Owner
MNPR	Monopar Therapeutics Inc	2018-01-08	10 percent owner

Gem Pharmaceuticals Llc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Gem Pharmaceuticals Llc Ownership Network

Ownership Network List of Gem Pharmaceuticals Llc

No Data

Ownership Network Relation of Gem Pharmaceuticals Llc

Gem Pharmaceuticals Llc Owned Company Details

What does Monopar Therapeutics Inc do?

Who are the key executives at Monopar Therapeutics Inc?

Gem Pharmaceuticals Llc is the 10 percent owner of Monopar Therapeutics Inc. Other key executives at Monopar Therapeutics Inc include Chief Operating Officer Andrew Cittadine , Chief Financial Officer Kim R Tsuchimoto , and director & Chief Executive Officer Chandler Robinson .

Monopar Therapeutics Inc (MNPR) Insider Trades Summary

Over the past 18 months, Gem Pharmaceuticals Llc made no insider transaction in Monopar Therapeutics Inc (MNPR). Other recent insider transactions involving Monopar Therapeutics Inc (MNPR) include a net purchase of 128,508 shares made by Andrew Cittadine , and a net purchase of 1,550 shares made by Karthik Radhakrishnan .

In summary, during the past 3 months, insiders sold 0 shares of Monopar Therapeutics Inc (MNPR) in total and bought 1,550 shares, with a net purchase of 1,550 shares. During the past 18 months, 0 shares of Monopar Therapeutics Inc (MNPR) were sold and 27,252 shares were bought by its insiders, resulting in a net purchase of 27,252 shares.

Monopar Therapeutics Inc (MNPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Monopar Therapeutics Inc Insider Transactions

No Available Data

Gem Pharmaceuticals Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Gem Pharmaceuticals Llc. You might contact Gem Pharmaceuticals Llc via mailing address: C/o 1000 Skokie Blvd., Suite 350, Wilmette Il 60091.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.